Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Novartis
Julphar
Merck
Express Scripts
Argus Health
Mallinckrodt
QuintilesIMS
Healthtrust

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,536,130

« Back to Dashboard

Which drugs does patent 8,536,130 protect, and when does it expire?

Patent 8,536,130 protects NUCYNTA ER and is included in one NDA.

This patent has eleven patent family members in eleven countries.
Summary for Patent: 8,536,130
Title:Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain
Abstract: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.
Inventor(s): Christoph; Thomas (Aachen, DE), Friderichs; Elmar (Stolberg, DE), Koegel; Babette-Yvonne (Langerwehe-Hamich, DE), Meen; Murielle (Ayguesvives, FR)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:12/850,208
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,536,130

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-001 Aug 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ➤ Sign Up
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-002 Aug 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ➤ Sign Up
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-003 Aug 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ➤ Sign Up
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-004 Aug 25, 2011 RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ➤ Sign Up
Depomed Inc NUCYNTA ER tapentadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 200533-005 Aug 25, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,536,130

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2007 012 165Mar 12, 2007

International Patents Family Members for US Patent 8,536,130

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2016056188 ➤ Sign Up
Japan 2010520907 ➤ Sign Up
Japan 6081337 ➤ Sign Up
Japan 2013256540 ➤ Sign Up
Croatia P20140280 ➤ Sign Up
Spain 2452830 ➤ Sign Up
European Patent Office 2117525 ➤ Sign Up
Denmark 2117525 ➤ Sign Up
Germany 102007012165 ➤ Sign Up
Cyprus 1115455 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
AstraZeneca
Farmers Insurance
Johnson and Johnson
McKesson
QuintilesIMS
Harvard Business School
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot